Learn about progress on health equity and anti-racism efforts in Seattle Children’s fourth quarterly report.

Projects

Blood Cancers

Our team has been developing a new CD200R-based IFP to improve in vivo anti-tumoral T-cell function against acute myeloid leukemia (AML).

Solid Tumors

In mouse models of ovarian and pancreatic cancers, mice with our IFP-enhanced cell therapy were able to destroy repeated additions of tumor cells, whereas control T cells became dysfunctional and ineffective.

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.